Ocuphire Pharma Inc reports results for the quarter ended in June - Earnings Summary

Opus Genetics

13/08/2024 14:00

* Ocuphire Pharma Inc  OCUP.OQ  reported a quarterly
adjusted loss
of 30 cents​​ per share for the quarter ended in June, lower
than the same quarter last year, when the company reported EPS
of -24 cents.  The mean expectation of four analysts for the
quarter was for a loss of 25 cents per share. Wall Street
expected results to range from -31 cents to -14 cents per share.
    * Revenue fell 69.7% to $1.11 million from a year ago;
analysts
expected $2.46 million. 
    * Ocuphire Pharma Inc's reported EPS for the quarter was a
loss
of 30 cents​.
    * The company reported a quarterly loss of $7.77 million.
    * Ocuphire Pharma Inc shares had risen by 8.2% this
quarter and
lost 45.0% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 31.9%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for Ocuphire Pharma
Inc is $19.00 
This summary was machine generated from LSEG data August 13 at
01:00 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jan. 1 0001       -0.25          -0.30          Missed
 Mar. 31 2024      -0.13          -0.29          Missed
 Dec. 31 2023      -0.05          -0.21          Missed
 Sep. 30 2023      -0.22          0.25           Beat